Risk of mortality (including sudden cardiac death) and major cardiovascular events in atypical and typical antipsychotic users: a study with the general practice research database
- PMID: 24455199
- PMCID: PMC3888674
- DOI: 10.1155/2013/247486
Risk of mortality (including sudden cardiac death) and major cardiovascular events in atypical and typical antipsychotic users: a study with the general practice research database
Abstract
Objective. Antipsychotics have been associated with increased cardiac events including mortality. This study assessed cardiac events including mortality among antipsychotic users relative to nonusers. Methods. The General Practice Research Database (GPRD) was used to identify antipsychotic users, matched general population controls, and psychiatric diseased nonusers. Outcomes included cardiac mortality, sudden cardiac death (SCD), all-cause mortality (excluding suicide), coronary heart disease (CHD), and ventricular arrhythmias (VA). Sensitivity analyses were conducted for age, dose, duration, antipsychotic type, and psychiatric disease. Results. 183,392 antipsychotic users (115,491 typical and 67,901 atypical), 544,726 general population controls, and 193,920 psychiatric nonusers were identified. Nonusers with schizophrenia, dementia, or bipolar disorder had increased risks of all-cause mortality compared to general population controls, while nonusers with major depression had comparable risks. Relative to psychiatric nonusers, the adjusted relative ratios (aRR) of all-cause mortality in antipsychotic users was 1.75 (95% CI: 1.64-1.87); cardiac mortality 1.72 (95% CI: 1.42-2.07); SCD primary definition 5.76 (95% CI: 2.90-11.45); SCD secondary definition 2.15 (95% CI: 1.64-2.81); CHD 1.16 (95% CI: 0.94-1.44); and VA 1.16 (95% CI: 1.02-1.31). aRRs of the various outcomes were lower for atypical versus typical antipsychotics (all-cause mortality 0.83 (95% CI: 0.80-0.85); cardiac mortality 0.89 (95% CI: 0.82-0.97); and SCD secondary definition 0.76 (95% CI: 0.55-1.04). Conclusions. Antipsychotic users had an increased risk of cardiac mortality, all-cause mortality, and SCD compared to a psychiatric nonuser cohort.
Figures


Similar articles
-
Risk of Mortality (including Sudden Cardiac Death) and Major Cardiovascular Events in Users of Olanzapine and Other Antipsychotics: A Study with the General Practice Research Database.Cardiovasc Psychiatry Neurol. 2013;2013:647476. doi: 10.1155/2013/647476. Epub 2013 Dec 14. Cardiovasc Psychiatry Neurol. 2013. PMID: 24416588 Free PMC article.
-
Atypical antipsychotic drugs and the risk of sudden cardiac death.N Engl J Med. 2009 Jan 15;360(3):225-35. doi: 10.1056/NEJMoa0806994. N Engl J Med. 2009. PMID: 19144938 Free PMC article.
-
A nationwide study of the risk of all-cause, sudden death, and cardiovascular mortality among antipsychotic-treated patients with schizophrenia in Taiwan.Schizophr Res. 2021 Nov;237:9-19. doi: 10.1016/j.schres.2021.08.015. Epub 2021 Aug 31. Schizophr Res. 2021. PMID: 34478937
-
Antibiotics for secondary prevention of coronary heart disease.Cochrane Database Syst Rev. 2021 Feb 23;2(2):CD003610. doi: 10.1002/14651858.CD003610.pub4. Cochrane Database Syst Rev. 2021. PMID: 33704780 Free PMC article.
-
Assessment on Implantable Defibrillators and the Evidence for Primary Prevention of Sudden Cardiac Death [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Jun 26. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Jun 26. PMID: 25356453 Free Books & Documents. Review.
Cited by
-
Pharmacologic treatment and SUDEP risk: A nationwide, population-based, case-control study.Neurology. 2020 Nov 3;95(18):e2509-e2518. doi: 10.1212/WNL.0000000000010874. Epub 2020 Sep 23. Neurology. 2020. PMID: 32967928 Free PMC article.
-
Association of Antipsychotic Polypharmacy and Two-Year All-Cause Mortality: A Population-Based Cohort Study of 33,221 Italian Continuous Users.J Clin Med. 2024 Apr 3;13(7):2073. doi: 10.3390/jcm13072073. J Clin Med. 2024. PMID: 38610838 Free PMC article.
-
Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls.World Psychiatry. 2017 Jun;16(2):163-180. doi: 10.1002/wps.20420. World Psychiatry. 2017. PMID: 28498599 Free PMC article.
-
Neurological Disorders and Risk of Arrhythmia.Int J Mol Sci. 2020 Dec 27;22(1):188. doi: 10.3390/ijms22010188. Int J Mol Sci. 2020. PMID: 33375447 Free PMC article. Review.
-
Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study.BMJ. 2016 May 31;353:i2550. doi: 10.1136/bmj.i2550. BMJ. 2016. PMID: 27245699 Free PMC article.
References
-
- Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Antipsychotics and the risk of sudden cardiac death. Archives of General Psychiatry. 2001;58(12):1161–1167. - PubMed
-
- Enger C, Weatherby L, Reynolds RF, Glasser DB, Walker AM. Serious cardiovascular events and mortality among patients with schizophrenia. Journal of Nervous and Mental Disease. 2004;192(1):19–27. - PubMed
-
- Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs. 2007;21(11):911–936. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources